Neoadjuvant chemotherapy and radiotherapy in locally advanced esophagus carcinoma: long-term results
| Autor: | Jose Juan Illarramendi, Miguel Angel Dominguez, Fernando Arias, Juan José Valerdi, Rafael López, Martín Tejedor, Enrique Martínez |
|---|---|
| Rok vydání: | 1993 |
| Předmět: |
Adult
Male Cancer Research medicine.medical_specialty Time Factors Esophageal Neoplasms Vindesine medicine.medical_treatment Bleomycin Antineoplastic Combined Chemotherapy Protocols medicine Carcinoma Humans Radiology Nuclear Medicine and imaging Prospective Studies Esophagus Aged Retrospective Studies Chemotherapy Radiation Epithelioma business.industry Esophageal disease Middle Aged medicine.disease Combined Modality Therapy Survival Analysis Surgery Radiation therapy Survival Rate Regimen medicine.anatomical_structure Oncology Chemotherapy Adjuvant Spain Carcinoma Squamous Cell Female Cisplatin business medicine.drug Follow-Up Studies |
| Zdroj: | International journal of radiation oncology, biology, physics. 27(4) |
| ISSN: | 0360-3016 |
| Popis: | Purpose: A prospective study with neoadjuvant chemotherapy and radiotherapy in patients with locally advanced esophagus carcinoma for evaluating: toxicity, response rate, pattern of recurrence, and survival after a long follow-up. Methods and Materials: Between 1983–1988, 40 patients with locally advanced squamous cell carcinoma of the thoracic esophagus were entered into a prospective trial of neoadjuvant chemotherapy and radiotherapy. Eight patients (20%) were Stage 11 and 32 patients (80%) were Stage 111, according to American Joint Committee staging criteria. Neoadjuvant chemotherapy consisted of two cycles with cisplatin (120 mg/m2 day 1), vindesine (3 mg/m2 days 1, 8, 15, and 22) and bleomycin (10 mg/m2 days 3 to 6). Second cycle was initiated on day 29. Radiation therapy was administered 2–4 weeks after completion of chemotherapy, with a total dose on tumor of 60 Gy. Results: Two patients died from treatment-related toxicity. Complete response was observed in 20 patients (53%) and symptomatic improvement in 31 patients (82%). The median survival was 11 months, with an actuarial survival at 1 year of 45%, 3 year 20%, and 5 years 15%. Significantly (p < 0.05) longer survival was observed in patients with Stage 11 (median survival 18 months) vs. Stage III (median survival 10 months). The pattern of failure was predominantly local/regional (62%). Conclusion: This treatment scheme is an effective and tolerable regimen but long-term survival was poor. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|